Hyperbaric oxygen therapy for long COVID (HOT-LoCO), an interim safety report from a randomised controlled trial.

ABSTRACT:

Background

With ~ 50 million individuals suffering from post-COVID condition (PCC), low health related quality of life (HRQoL) is a vast problem. Common symptoms of PCC, that persists 3 months from the onset of COVID-19 are fatigue, shortness of breath and cognitive dysfunction. No effective treatment options have been widely adopted in clinical practice. Hyperbaric oxygen (HBO₂) is a candidate drug.

Methods

The objective of this interim analysis is to describe our cohort and evaluate the safety of HBO₂ for post covid condition. In an ongoing randomised, placebo-controlled, double blind, clinical trial, 20 previously healthy subjects with PCC were assigned to HBO₂ or placebo. Primary endpoints are physical domains in RAND-36; Physical functio

SUBMITTER: Kjellberg A 

PROVIDER: S-EPMC9854077 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature